Skip to Content

Ivan P. Uray, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Clinical Cancer Prevention, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
Instructor, Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX

Bio Statement

Our aim is to establish preventive therapy in high risk individuals that efficiently suppresses AP-1 activity due to estrogenic stimulation of mammary epithelial cells. A primary factor activated by estrogen is AP-1, a critical regulator of breast cell growth and invasion and a marker of poor prognosis in breast cancer. The goal of this proposal is to investigate how activation of the AP-1 transcription factor by estrogen regulates estrogen-regulated genes, mammary tumor development and breast cancer growth. Specifically, we will characterize the molecular environment and associated proteins required for the collaborative interaction of ER and AP-1, study the potential of a dominant negative AP-1 protein to suppress oncogene-induced mammary tumor formation and determine its tumor suppressive potential in vivo.

I have comprehensive background in molecular and cellular biology and completed postdoctoral training in cancer prevention research. In my postdoctoral position I have characterized the interaction of AP-1 with retinoid receptors to up-regulate the growth suppressive gene IGFPB6. At the Department of Clinical Cancer Prevention I am establishing a high content imaging facility which will greatly further our ability to perform quantitative cell based assays with multiparametric readouts. Such experiments are particularly suitable to characterize the interactions of distinct transcription factors, study their impact on gene expression and cell cycle on a cell-by-cell basis. Given the necessary expertise, and my interest in nuclear receptor biology and revealing novel mechanisms by which nuclear hormone receptors can be targeted to block cancer formation, I will contribute to the success of the proposed research.


Office Address

The University of Texas MD Anderson Cancer Center
Basic Science Research Building
1515 Holcombe Blvd.
Unit Number: 1013
Houston, TX 77030
Room Number: S7.8116A
Phone: 713-834-6358
Fax: 713-834-6350

Education & Training

Degree-Granting Education

2001 University of Debrecen Health Science, Debrecen, Hungary, PHD, Biochemistry and Molecular Biology
1994 University Medical School, Debrecen, Hungary, MD, General Medicine

Postgraduate Training

2003-2007 Postdoctoral Associate, Breast Cancer, Baylor College of Medicine, Houston, TX, Dr. Powel Brown
1999-2003 Postdoctoral Fellow, Molecular Cardiology, The University of Texas at Houston, Health Science Center, Houston, TX
1995-1996 Visiting Research Fellow, Pharmacology, The University of Texas at Houston, Health Science Center, Houston, TX


Other Appointments/Responsibilities

Director of Chemoprevention Screening Resource, The University of Texas MD Anderson Cancer Center, Houston, TX, 2009-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Sárvári AK, Veréb ZJ, Uray IP, Fesüs L and Balajthy Z. Atypical antipsychotics induce both proinflammatory and adipogenic gene expression in human adipocytes in vitro. Biochem Biophys Res Comm. In Press.
2. Uray IP, Shen Q, Seo HS, Kim H, Lamph WW, Bissonnette RP, Brown PH. Rexinoid-induced expression of IGFBP-6 requires RARbeta-dependent permissive cooperation of retinoid receptors and AP-1. J Biol Chem 284(1):345-353, 1/2009. e-Pub 10/2008. PMCID: PMC2610495.
3. Shen Q, Uray IP, Li Y, Zhang Y, Hill J, Xu XC, Young MR, Gunther EJ, Hilsenbeck SG, Colburn NH, Chodosh LA, Brown PH. Targeting the AP-1 Transcription Factor for the Prevention of Estrogen Receptor (ER) –negative Mammary Tumors. Cancer Prev Res (Phila Pa) 1(1):44-55, 6/2008. e-Pub 3/2008. PMCID: PMC2577387.
4. Shen Q,Uray IP, Li Y, Krisko TI, Strecker TE, Kim HT, Brown PH. The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors. Oncogene 27(3):366-77, 1/2008. e-Pub 7/2007. PMID: 17637753.
5. Uray IP, Brown PH. Prevention of breast cancer: current state of the science and future opportunities. Expert Opin Investig Drugs 15(12):1583-600, 12/2006. PMID: 17107283.
6. Shen Q, Zhang Y, Uray IP, Hill JL, Kim HT, Lu C, Young MR, Gunther EJ, Hilsenbeck SG, Chodosh LA, Colburn NH, Brown PH. The AP-1 Transcription Factor Regulates Postnatal Mammary Gland Development. Dev Biol 295(2):589-603, 7/2006. e-Pub 4/2006. PMID: 16678816.
7. Srinivas H, Xia D, Moore NL, Uray IP, Kim H, Ma L, Weigel NL, Brown PH, Kurie JM. Akt phosphorylates and suppresses the transactivation of retinoic acid receptor alpha. Biochem J 395(3):653-62, 5/2006. PMCID: PMC1462695.


1. Yang P, Pirman D, Ding X, Brown PH, Uray IP. Cancer Preventive Rexinoids Induce a Shift in Cellular Lipid Composition to Enhance n-3 PUFA Content in Breast Epithelial Cells. Metabolic Signaling & Disease, Cold Spring Harbor, MD. 8/2013.
2. Uray IP, Bissonnette RP, Brown PH. Cellular Neutral Lipid Content is a Novel Biomarker of Cancer Preventive Activity. 10th AACR Frontiers of Cancer Prevention Research Meeting, 10/2011.
3. Uray IP, Yang, P, Bissonnette RP, Brown PH. Cancer Preventive Rexinoids Modulate Lipid Composition if Mammary Epithelial Cells and Suppress Cell Growth. Keystone Symposium, Lipid Biology and Lipotoxicity, 5/2011.

Grant & Contract Support

Title: Alpha1-adrenergic Signaling as a Target for Breast Cancer Prevention
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Principal Investigator
Duration: 9/1/2014 - 8/31/2017
Title: Targeting the lipid synthesis enzyme, DGAT1, for breast cancer prevention
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 8/1/2013 - 7/31/2015
Title: 15-lipoxygenase-1 Transcriptional Activation to Molecularly Target Colon Cancer
Funding Source: IRG
Role: Collaborator
Principal Investigator: Shureiqi
Duration: 7/1/2012 - 6/30/2014
Title: High Throughput Search for a Combination Cancer Prevention Treatment
Funding Source: DFI
Role: Principal Investigator
Duration: 8/1/2011 - 1/31/2014
Title: High Content Analysis to Identify Biomarkers for Chemopreventive Drug Activity
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Principal Investigator: Mancini
Duration: 9/1/2008 - 8/31/2010

Last updated: 7/24/2014